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Dr Arvind K. Agnihorti (Boston, Mass). Thank you, Dr Cohn,
and thank you, Dr Toole, for this interesting study about a poten-
tially useful adjunct in cardiac surgery. I have 2 comments and
then a few questions.
As I read your article, I thought about bleeding in postoperative
cardiac surgery and how we deal with a continuum from coagulop-
athy to surgical sources of bleeding; the 2 obviously are interre-
lated, and one can beget the other. In this article, which is
retrospective, your surgeons tried to determine whether the pa-
tients had a coagulopathy or a surgical source of bleeding and
then proceeded to either reoperate on them or potentially to use
this drug. Therefore these are really 2 different populations of pa-
tients, and I think that limits the way that we can approach a com-
parison, as it was done in your study.
The second thing I wanted to point out was that the use of this
drug did not appear to improve the outcomes for your patients.
Therefore another way to look at this study is that reoperation in
the absence of factor VII is also a safe and efficacious way to
deal with postoperative hemorrhage, and I was a bit surprised
that the use of this drug did not show any apparent reduction in
cost.
I have a couple of questions. The first has to do with safety. In
the group of patients who received factor VII, 25% (n ¼ 3) ulti-
mately required an operation. In that group 2 of 3 had a complica-
tion that might be attributed to stroke: 1 had a pulmonary
embolism, and 1 had renal failure. I want you to comment on
the possible risk of application of this drug in a patient who has sur-
gical bleeding and is being treated for coagulopathy.
Dr Toole. Thank you very much for those comments. I think
that is a very important point and one that we have gone to great
lengths to minimize: the administration of a thrombogenic drug
to a patient with a relatively normal coagulation system. As you
have pointed out, there seems to be a continuum from surgical
bleeding to coagulopathy. The definition of surgical bleeding at
our institution might be changing, as referenced by the change
in our practices from reoperation to administering factor VII to al-
most everybody. I think that the reason we only found 1 patient
with surgical bleeding in the factor VII group is that a lot of things
that we would consider surgical bleeding might have stopped with
factor VII. Examples would be sternal wires and small mediastinal
vessels.
Your concerns about safety are appropriate. Certainly we did
not have the statistical power to make any comments about that.
I think it is a point worth making that designing a study to detect1476 The Journal of Thoracic and Cardiovascular Surdifferences in safety is extremely difficult. Gill, in the Journal of
Thoracic and Cardiovascular Surgery in 2009, consented more
than 2600 patients and only dosed about 170. The amount of
work to consent patients and then randomize them into a study
is enormous. In our study only 5% of high-risk patients had signif-
icant postoperative bleeding. This is an inherent problem with pro-
spectively studying these patients. Even with their cohort of 170
patients, they believed that they were underpowered to make any
comment on statistical significance as far as safety.
Dr Agnihotri. Did you look at postoperative creatinine values
in your patients? I noted that the renal failure rate was not statisti-
cally different, but did you see any increase in the treatment group
in terms of their peak creatinine values?
Dr Toole. We did not see that.
Dr Agnihotri. You chose a dose of about 90 mg/kg as a single
dose. Others have used smaller doses and given multiple smaller
doses. Do you have experience with that, and can you comment
on why you chose that dose?
Dr Toole. We began using the 90 mg/kg dose because that is the
recommended dose set forth by the manufacturer for the treatment
of patients with hemophilia. More recent studies suggest that ear-
lier dosing and smaller doses, with ranges between 30 and 70 mg/
kg, might be effective. To some extent, we have adopted that
strategy.
Dr Agnihotri. Thank you very much.
Dr SimonMoten (Melbourne, Australia). At our institution, we
have a large experience with the use of recombinant factor VII and
are currently involved in a randomized controlled trial for its use in
the operative setting. My comment and question is that in the post-
operative setting, if people are bleeding, the important factor is the
timing at the time of intervention when you realize that patients do
require further intervention to correct their bleeding, either return
to the operating theater or other measures. In your study did you
find that there was any difference in the timing between the 2
groups that might have led to a difference in their outcomes? Cer-
tainly I believe that earlier intervention in this group is important
for reducing the overall complication rate.
Dr Toole. I agree with you wholeheartedly. We did not specif-
ically look at timing. The bleeding criteria that we used measured
chest tube output for the 2 hours before intervention. Once a patient
reached the criteria for either reoperation or dosing with factor VII,
no more than 2 hours had passed. However, we did have several
patients, especially in the earlier reoperation group, who had mod-
erate chest tube output not meeting the bleeding criteria overnight
but that increased, and these patients underwent reoperation on the
following day.
Dr Domenico Paparella (Bari, Italy). It is hard to define coa-
gulopathy. As you know, there are several reasons why we can
have coagulopathy after cardiac surgery. It can be platelet dysfunc-
tion, hyperfibrinolysis, or coagulation factor consumption. Did
you try to analyze the reason for coagulopathy by using any
point-of-care test?
Dr Toole. No, we did not.
Dr Paparella. Okay. I think that makes the choice of adminis-
tering recombinant factor VII to all bleeding patients not very bal-
anced because you do not know why your patients are bleeding.
Dr Toole. Our criteria for giving factor VII required that coag-
ulation test results be relatively normal, bywhich Imean a a plateletgery c June 2011
Uber et al Perioperative Managementcount of greater than 100,000, an international normalized ratio of
less than 1.5, a complete reversal of the partial thromboplastin
time, and a fibrinogen level of greater than 200, but we did not nec-
essarily use a point-of-care test to adjust those. I think what you are
referring to is a thromboelastogram, which we did not routinely
use on all bleeding patients postoperatively.
DrG.Hossein Almassi (Milwaukee, Wis). Did you have in your
group of factor VII recipients any patients with diseases that would
predispose to bleeding, such as myelomonocytic leukemia, in
which no matter what you do they bleed, or any other type of
malignancy that would predispose them to it? Do you have any
experience in that regard?
Dr Toole. We did not have any patients with any of those con-
ditions or any personal or family history of bleeding disorders.
Dr A. W. Atkinson (Raleigh, NC). The earlier comment that
you do not have any quantitative defect in your clinical assessment
of why the patient is bleeding and yet he or she is bleeding was in-
teresting, and it appears that when you give some patients factor
VII, they stop bleeding. It just might be that we are not doing
the right test yet. Maybe we ought to get a quantitative level for
factor VII or some other proton, partial thromboplastin time,
something we are not doing right so we know when to give this
drug. It appears that there is a relative deficiency of this part ofThe Journal of Thoracic and Carthe cascade, and we just have not learned to test for it yet. How
about that?
Dr Toole. I agree with you. It is difficult to assess exactly what
the deficiency is unless there is a specific abnormality that shows
up in the coagulation laboratory studies. We try very hard to cor-
rect all of those: first so we do not have to give the patient factor
VII if they do not need it, but second because once the factor
VII is given, it relies on all of those downstream components of
the clotting cascade to get the job done. Giving a patient with
coagulation abnormalities factor VII is not likely to help them.
Dr Atkinson. There was not anybody who was still bleeding
after you fixed the surgical problem if it existed and you gave
them factor VII, right?
Dr Toole. That is correct.
Dr Lawrence H. Cohn (Boston, Mass). I have one question.
You said it was a very expensive drug. Can you give us a sense
of the sort of average cost of the use of this recombinant factor
in these patients?
Dr Toole. Factor VII itself costs about $1000 a milligram. We
gave it in a 90 mg/kg dose. Not everybody uses that dose. Unfortu-
nately, our average patient in South Carolina weighs between 90
and 100 kg, and therefore our average cost of factor VII is about
$9,000 per dose.diovascular Surgery c Volume 141, Number 6 1477
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